Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical stage biotechnology company, and Delta4, an Austrian […]
News
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological and […]
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology […]
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
Delta4 expands Team and tackles new indications
Following our Financing in March 2021 and our move into new premises in July 2021 we are continuing to expand […]
Office News – July ’21
We are excited to announce that Delta4 has moved into a new office in the 8th district, close to the city […]
Alfred Steininger to Join Delta4 as CFO
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings […]
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed […]
Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in […]